Formic Acid

Formic Acid

SCHEMBL4664307

CCN(CC)CCn1ccc2cc(-c3cc(Nc4ccc(NS(=O)(=O)c5ccc(OC)cc5)cc4)ncn3)ccc21.O=CO

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 4/20 0.51
SCN9A Q15858 1/20 0.41
EGFR P00533 2/20 0.40
ABL1 P00519 6/20 0.39
BCR P11274 6/20 0.39
GSK3B P49841 2/20 0.39
AURKA O14965 1/20 0.39
BPTF Q12830 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
GFER P55789 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
FAM20C Q8IXL6 1/20 0.38
KIT P10721 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL4665624 0.96 HTR6 (0.46) HTR6ABL1BCRGSK3BAURKA
Formic Acid SCHEMBL4667521 0.95 HTR6 (0.46) HTR6ABL1BCRGSK3BAURKA
Formic Acid SCHEMBL4667457 0.93 HTR6 (0.51) HTR6SCN9AEGFRBPTFALDH1A1
Formic Acid SCHEMBL4665821 0.92 HTR6 (0.50) HTR6SCN9AEGFRABL1BCR
Formic Acid SCHEMBL4667419 0.91 HTR6 (0.48) HTR6SCN9AEGFRABL1BCR
SCHEMBL4664297 0.89 HTR6 (0.54) HTR6EGFRABL1BCRGSK3B
Formic Acid SCHEMBL4666208 0.89 HTR6 (0.46) HTR6EGFRBPTFALDH1A1GAA
Formic Acid SCHEMBL4665760 0.88 HTR6 (0.45) HTR6SCN9AEGFRBPTFALDH1A1
Formic Acid SCHEMBL4666109 0.88 HTR6 (0.49) HTR6SCN9AEGFRGSK3BBPTF
Formic Acid SCHEMBL4664378 0.87 HTR6 (0.45) HTR6SCN9AEGFRABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 HTR6 826/4885SCN9A 1693/4885EGFR 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.